Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shanghai Green Valley

- PMLiVE

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category

- PMLiVE

Chi-Med cues up two more regulatory filings in cancer

Hong Kong based firm reports strong sales in first marketed product

- PMLiVE

Hansoh Pharma shares head skyward after HKEX debut

Adds to China's growing presence in life sciences

- PMLiVE

Swedish biotech Calliditas signs China licensing deal for autoimmune candidate

IgA nephropathy more common in China

- PMLiVE

AmyPore gets EU backing for Alzheimer’s and Parkinson’s therapy

Novel chimeric peptide ready to start clinical trials

- PMLiVE

Bicycles Therapeutics enters dementia discovery with venture capital fund

Ambitious UK biotech expands research scope

- PMLiVE

Chi-Med goes for third IPO in Hong Kong

New listing follows first product launch

Live Webinar: China in the fast lane: How to play and win in the world’s hottest emerging market

Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST

Research Partnership

Novartis day

Novartis claims first place for psoriasis drug Cosentyx in China

Trial data from China helped support filing

Biogen Idec building

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

Also considering a trial in preclinical Alzheimer’s subjects

- PMLiVE

Innovent gears up for PD-1 inhibitor launch in China

Analysts say the approval marks a move away from developing ‘me-too’ drugs

- PMLiVE

GW Pharma’s cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links